OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will ...
A surgeon examining a patient's brain in an operating room ... On February 3rd, TD Cowen increased Boston Scientific Corporation’s (NYSE:BSX) target price to $115 from $110 and reiterated ...
New research suggests that certain antidepressants may not only help with depression but also improve cognitive functions ...
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and ...
Blood-Brain Barrier Technology ... In conclusion, Alector’s presentation at the TD Cowen Conference underscored its commitment to advancing therapies for neurodegenerative diseases.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...